Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
NEW YORK, Jan. 28, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
http://www.reportlinker.com/p01089006/Diabetes-Therapeutics-Market-in-India-to-2018---Rapid-Uptake-of-DPP-IV-Inhibitors-GLP-1-Agonists-and-Expanding-Insulin-Segment-to-Drive-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
Summary
GBI Research, the leading business intelligence provider, has released its latest research "Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth", which provides insights into the India anti-diabetes market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. Insights into the diabetes epidemiology, cost of therapy, research and development pipeline and the promising molecules which are anticipated to be launched by 2018 are discussed in the report. The report provides an in-depth analysis type 1 and type 2 diabetes. The report provides an in-depth analysis on oral anti-diabetics agents, insulin products and drivers and barriers that could significantly impact the overall anti-diabetes market during the forecast period. Additionally, it explores the competitive landscape, including benchmarking the top companies in the market and the key issues and trends that are likely to have an impact on the Indian diabetes market during the forecast period. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also discussed in the report.
GBI Research's analysis revealed that the overall anti-diabetes market in India was worth $680.3m in 2011 and is projected to grow at a CAGR of 11.3% between 2011 and 2018 to reach $1,446m in 2018. High and growing diabetes population in the country, rising obese and geriatric population, and rapid market adoption of drugs from the classes such as Dipeptidyl Peptidase 4 (DPP-4) inhibitors, Glucagon-Like Peptide (GLP)-1, Sodium-Glucose Transport Proteins (SGLT-1) and others would drive the anti-diabetes market in the forecast period. The R&D product pipeline for DM, dominated by OAD agents, consists of around 200 molecules at various stages of clinical development. Paradoxically, type 2 diabetes therapeutics market, crowded with many generics and branded generics drug products, is being seen as a significant growth opportunity for new patent protected products owing to high prevalence, progressive nature of the disease and considerably high unmet needs. Of overall R&D pipeline molecules, more than 90% are being studied for the treatment of type 2 DM.
Many multinational companies, such as Novartis, Eli Lilly, are engaged in setting up strategic marketing and distribution agreements with domestic players to improve their patient base and so the market share. Growing at a double digit year on year growth rate, the Indian anti-diabetics market is very promising and offers lucrative opportunities to both domestic as well as foreign pharmaceutical players.
Scope
- Data and analysis on the Indian diabetes therapeutics market
- Annualized market data for the diabetes therapeutics market from 2004 to 2011, with forecasts to 2018 for type 1 and type 2 diabetes.
- Epidemiological data on type 1 and type 2 diabetes along with market size, annual cost of therapy, unmet needs and economic burden of diabetes.
- Key drivers and restraints that have had a significant impact on the market.
- Major trends and issues which are likely to have a significant impact on overall diabetes therapeutics market in India
- Competitive landscape of the diabetes therapeutics market including top companies benchmarking. The key companies studied in this report are Novo Nordisk, Sanofi, Novartis, Eli Lilly, Merck, Abbott, USV, Sun Pharma, Biocon and Wockhardt.
- Key M&A activities and licensing agreements, major deals that took place in last four years in Indian diabetes therapeutics market.
Reasons to buy
- Align their product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
Table of Contents
1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 10
2 Diabetes Therapeutics Market in India to 2018 - Overview 11
2.1 Diabetes Mellitus - A Global Overview 11
3 Diabetes Therapeutics Market in India - Introduction 12
3.1 Type 1 Diabetes Mellitus 12
3.1.1 People at Risk 12
3.1.2 Risk Factors for Type 1 Diabetes 12
3.1.3 Symptoms 12
3.2 Type 2 Diabetes Mellitus 13
3.2.1 People at Risk 13
3.2.2 Risk Factors for Type 2 Diabetes 13
3.2.3 Symptoms 13
3.3 Gestational Diabetes Mellitus 13
3.3.1 Risk Factors for Gestational Diabetes Mellitus 13
3.4 Diagnosis of Diabetes Mellitus 14
3.5 Diabetes Treatment Guidelines - India 15
3.5.1 Introduction 15
3.5.2 Prevention of Diabetes 15
3.5.3 Diabetes Treatment 15
3.6 Diabetes Mellitus Complications 16
4 Diabetes Therapeutics Market in India to 2018 - Major Drug Classes 17
4.1 Sulfonylureas 17
4.1.1 Introduction 17
4.1.2 Mechanism of Action 17
4.1.3 Major Drugs 18
4.2 Thiazolidinediones 18
4.2.1 Introduction 18
4.2.2 Mechanism of Action 18
4.2.3 Example 18
4.3 Biguanides 19
4.3.1 Introduction 19
4.3.2 Mechanism of Action 19
4.3.3 Drug Products 19
4.4 Meglitinides 20
4.4.1 Introduction 20
4.4.2 Mechanism of Action 20
4.4.3 Major Drugs 20
4.5 Alpha-Glucosidase Inhibitors 21
4.5.1 Introduction 21
4.5.2 Mechanism of Action 21
4.5.3 Major Drugs 21
4.6 Glucagon-Like Peptide Analogs and Agonists 22
4.6.1 Description 22
4.6.2 Mechanism of Action 22
4.6.3 Major Drugs 22
4.7 Dipeptidyl Peptidase-4 Inhibitors 22
4.7.1 Description 22
4.7.2 Mechanism of Action 22
4.7.3 Major Drugs 23
4.8 Glucagon-Like Peptide-1 Analogs vs. Dipeptidyl Peptidase-4 Inhibitors 23
4.9 Insulin Preparations 23
4.9.1 Introduction 23
4.9.2 Types of Insulin 23
5 Diabetes Therapeutics Market in India to 2018 - Epidemiology 25
5.1 Introduction 25
5.2 Diabetes Population in India 27
5.3 Diagnosed Population 29
5.4 Treated Population 29
6 Diabetes Therapeutics Market in India to 2018 - Revenue Forecasts 30
6.1 Introduction 30
6.1.1 Oral Anti-Diabetics Market 31
6.1.2 Insulin Market 31
6.2 Annual Cost of Therapy 32
7 Diabetes Therapeutics Market in India to 2018 - Economic Burden of Diabetes in India 33
7.1 Economic Burden of Diabetes in India 33
7.1.1 Introduction 33
7.1.2 Healthcare Expenditure on Diabetes in India 33
7.2 Collaborative Efforts Necessary to Address the Rising Burden of Diabetes 34
8 Diabetes Therapeutics Market in India to 2018 - Drivers and Barriers 35
8.1 Market Drivers 35
8.1.1 Aging Population, Sedentary Lifestyle and Unhealthy Diet is Driving the Diabetic Population in India 35
8.1.2 Promising Molecules Offering Improved Clinical Outcomes Could Increase Patient Base on Therapy 35
8.1.3 Untapped Areas Offer Promising Opportunities to Pharmaceutical Companies 36
8.2 Market Barriers 36
8.2.1 Low Diagnosis and Prescription Rate 36
8.2.2 Highly Competitive Market Driven by Generics and Branded Generics Increases Pricing Pressure 36
8.2.3 High Out-of-Pocket and Low Healthcare Expenditure on Diabetes 37
9 Diabetes Therapeutics Market in India to 2018 - Unmet Needs 38
9.1 Introduction 38
9.2 High Cost of Therapy and Drug Safety Issues Affect Patient Compliance 38
9.3 Unmet Need Creates Opportunities for Pharmaceutical Companies 38
10 Diabetes Therapeutics Market in India to 2018 - Product Pipeline Analysis 39
10.1 Profiles of Promising Molecules in R&D Development 40
10.1.1 IN-105 (Oral Insulin) 40
10.1.2 NN9068/IDegLira/degludec +/- liraglutide 40
10.1.3 Dapagliflozin 41
10.1.4 Canagliflozin/TA-7284 42
10.1.5 Lixisenatide 42
10.1.6 Alogliptin 42
11 Diabetes Therapeutics Market in India to 2018 - Case Studies 43
11.1 Avandia Fallout Impact 43
11.1.1 Introduction 43
11.1.2 Cardiovascular Safety Issues 43
11.1.3 Impact on GlaxoSmithKline 43
11.1.4 Impact on Drug Approvals 43
11.2 Januvia from Merck an Example that Patented Products can succeed in India 44
11.2.1 Introduction 44
11.2.2 Improved Pharmacological Effect of DPP-4 Inhibitors Helped Rapid Adoption 44
11.2.3 Januvia and Janumet a New Growth Engine for Merck 44
11.2.4 Robust Approach Needed to Market a New Drug Product in India 44
11.2.5 Excellent Commercialization Strategy 45
11.2.6 Conclusion 45
12 Diabetes Therapeutics Market in India to 2018 - Major Trends and Issues 46
12.1 Biguanides Class is dominated by Generics 46
12.2 Evolving Oral Hypoglycemic Agents Resulting in Smaller Market Share Sulfonylureas 46
12.3 Increasing Competition in Dipeptidyl Peptidase-4 Inhibitor Class 46
12.3.1 DPP-4 Inhibitors Likely to Face Potential Competition from GLP-1 Agonists 46
12.4 Thiazolidinedione Class to Face Impact of Avandia Fallout 47
12.5 GLP-1 Agonists Must Demonstrate Better Safety and Efficacy Profiles to Compete with other Oral Hypoglycemic Class 47
12.6 Fierce Competition in the Insulin Market is Likely to Increase 48
12.7 Is Oral Insulin the Next Big Thing in the Insulin Market? 48
12.7.1 Introduction 48
12.7.2 Oral Insulin Not for All 48
12.7.3 Challenges to Overcome 48
12.7.4 Would it lead to Market Cannibalization? 49
12.8 India Diabetes Market: Setting up for the Biosimilars? 49
12.8.1 Introduction 49
12.8.2 Insulin Biosimilar Market 49
12.8.3 Sanofi's Lantus a Lucrative Target 49
12.8.4 Need for Dose Adjustments would Discourage Uptake of Biosimilars 50
12.8.5 Price Discounts Alone would be Insufficient 50
12.8.6 Strong Brand Promotion would be Necessary for Insulin Biosimilars 50
12.8.7 Collaborations and Licensing Agreements are Key 50
12.8.8 Conclusion 51
12.9 Sodium Glucose Co-Transporter2 Inhibitors: A New Class to Hit the Market? 51
12.10 Glucokinase Activators 51
12.11 Stem Cell Therapies: The Next Prospective Therapy for Diabetes? 52
12.11.1 Introduction 52
12.11.2 What are Stem Cells? 52
12.11.3 Stem Cell Therapies and Diabetes 52
12.11.4 Conclusion 52
12.12 Price Discounts a Decisive Factor in the Increasingly Competitive Anti-Diabetes Market 53
12.13 Favorable Government Polices to Promote Generics 53
12.14 Strategic Consolidation to Increase Growth Prospects 54
12.14.1 Introduction 54
12.14.2 Shift of Focus towards Rural and Class II-IV Towns 54
13 Diabetes Therapeutics Market in India to 2018 - Competitive Landscape 55
13.1 Novartis India Limited (Novartis India) 55
13.2 Novo Nordisk India Private Limited (Novo) 56
13.3 Eli Lilly and Company (India) Pvt. Ltd. (Eli Lilly) 57
13.4 Merck Sharp Dohme India 57
13.5 Abbott India Limited (Abbott India) 58
13.6 Sun Pharmaceutical Industries Limited (Sun Pharma) 59
13.7 USV Limited 60
13.8 Wockhardt Limited (Wockhardt) 61
13.9 Sanofi India Limited 62
13.10 Biocon Limited (Biocon) 63
14 Diabetes Therapeutics Market in India to 2018 - Strategic Consolidations 64
14.1 Introduction 64
14.2 Diabetology Entered into Licensing Agreement with USV for Capsulin on July 31, 2012 64
14.3 Merck Sharp & Dohme Entered into Co-Marketing Agreement with Sun Pharma on April 25, 2011 64
14.4 Eli Lilly and Company (India) Entered into Co-Promotion Agreement with Lupin on July 29, 2011 65
14.5 Sheffield Bio-Science Entered into Collaboration with Wockhardt on February 21, 2011 65
14.6 Eli Lilly Entered into Co-Promotion Agreement with Boehringer Ingelheim for Humalog and Linagliptin on October 3, 2011 65
14.7 Novartis India Entered into Co-Marketing Agreement with USV on December 31, 2008 65
14.8 Pfizer-Biocon Deal Called Off in March 2012 66
14.8.1 Impact Analysis 66
15 Diabetes Therapeutics Market in India to 2018 - Appendix 67
15.1 Market Definitions 67
15.2 Abbreviations 67
15.3 Bibliography 68
15.4 Research Methodology 69
15.4.1 Coverage 69
15.4.2 Secondary Research 70
15.4.3 Primary Research 70
15.5 Therapeutic Landscape 71
15.5.1 Market 73
15.6 Geographical Landscape 74
15.7 Pipeline Analysis 74
15.8 Competitive Landscape 74
15.8.1 Expert Panel Validation 74
15.9 Contact Us 74
15.10 Disclaimer 74
List of Tables
Table 1: Diabetes Market, India, Diagnosis, Blood Sugar Estimation and Interpretation, 2012 14
Table 2: Diabetes Market, India, Diagnosis, Oral Glucose Tolerance Test, Estimation and Interpretation (mg/dL), 2012 14
Table 3: Diabetes Market, India, Oral Hypoglycemic Agents, Sulfonylurea, 2012 17
Table 4: Diabetes Market, India, Oral Hypoglycemic Agents, Thiazolidinediones, 2012 18
Table 5: Diabetes Market, India, Oral Hypoglycemic Agents, Biguanides, 2012 19
Table 6: Diabetes Market, India, Oral Hypoglycemic Agents, Meglitinides, 2012 20
Table 7: Diabetes Market, India, Oral Hypoglycemic Agents, Alpha-glucosidase Inhibitors, 2012 21
Table 8: Diabetes Market, India, Treatment Usage Pattern (million), 2004-2011 28
Table 9: Diabetes Market, India, Treatment Usage Pattern (million), 2011-2018 28
Table 10: Diabetes Market, India, Anti-Diabetic Revenue ($m), 2004-2011 30
Table 11: Diabetes Market, India, Anti-Diabetic Revenue Forecast ($m), 2011-2018 30
Table 12: Diabetes Market, India, Annual Cost of Therapy ($), 2004-2011 32
Table 13: Diabetes Market, India, Annual Cost of Therapy Forecast ($), 2011-2018 32
List of Figures
Figure 1: Diabetes Market, India, Type 2 Diabetes Treatment Model, 2012 15
Figure 2: Diabetes Market, Global, Diabetes Prevalence, 2011 25
Figure 3: Diabetes Market, Global, Top 10 Diabetes Destinations, 2011 26
Figure 4: Diabetes Market, India, Diabetes Population (million), 2011 27
Figure 5: Diabetes Market, India, Treatment Usage Pattern (million), 2004-2018 28
Figure 6: Diabetes Market, India, Anti-diabetic Revenue Forecast ($m), 2004-2018 30
Figure 7: Diabetes Market, India, Annual Cost of Therapy ($), 2004-2018 32
Figure 8: Diabetes Market, India, Mean Diabetes-related Expenditure Per Person ($), 2011 33
Figure 9: Diabetes Market, India, Drivers and Barriers, 2012 35
Figure 10: Diabetes Market, India, Product Pipeline by Phase, 2012 39
Figure 11: Diabetes Market, India, Novartis India Limited, Diabetes Product Portfolio, 2012 55
Figure 12: Diabetes Market, India, Novo Nordisk, Diabetes Product Portfolio, 2012 56
Figure 13: Diabetes Market, India, Eli Lilly, Diabetes Product Portfolio, 2012 57
Figure 14: Diabetes Market, India, Merck Sharp Dohme, Diabetes Product Portfolio, 2012 57
Figure 15: Diabetes Market, India, Abbott India, Diabetes Product Portfolio, 2012 58
Figure 16: Diabetes Market, India, Sun Pharma, Diabetes Product Portfolio, 2012 59
Figure 17: Diabetes Market, India, USV Limited, Diabetes Product Portfolio, 2012 60
Figure 18: Diabetes Market, India, Wockhardt Limited, Diabetes Product Portfolio, 2012 61
Figure 19: Diabetes Market, India, Sanofi, Diabetes Product Portfolio, 2012 62
Figure 20: Diabetes Market, India, Biocon Limited, Diabetes Product Portfolio, 2012 63
Figure 21: GBI Research Market Forecasting Model 73
Companies Mentioned
Novartis India Limited (Novartis India)
Novo Nordisk India Private Limited (Novo)
Eli Lilly and Company (India) Pvt. Ltd. (Eli Lilly)
Merck Sharp Dohme India
Abbott India Limited (Abbott India)
Sun Pharmaceutical Industries Limited (Sun Pharma)
USV Limited
Wockhardt Limited (Wockhardt)
Sanofi India Limited
Biocon Limited (Biocon)
To order this report:
Therapy Industry: Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
_________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article